Opinion|Videos|December 3, 2025
Detailing the Exploration of Plixorafenib in CNS Malignancies
Author(s)Patrick Y. Wen, MD, Karisa C. Schreck, MD, PhD
Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the novel BRAF inhibitor plixorafenib and its ongoing evaluation in central nervous system malignancies.
Advertisement
Episodes in this series
Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the novel BRAF inhibitor plixorafenib and its ongoing evaluation in central nervous system malignancies.
Advertisement
Related to this article
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
The HER2-directed ADC produced confirmed responses across both biomarker-defined cohorts of advanced salivary gland carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
2
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
3
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
4
Dr Viansone on De-Escalating Chemotherapy Type and Duration in HER2-Positive Breast Cancer
5